AusperBio

Beyond's analysis on AusperBio

• 2026-10-08 — AusperBio to showcase long-term AHB-137 efficacy data at AASLD 2026
• 2026-08-28 — AusperBio secures $120 million Series C to push AHB‑137 toward Phase 3 and expand its HBV pipeline

Recent news mentioning AusperBio

• 2026-10-08 — AusperBio to Present Long-Term Follow-Up Data of AHB-137 Treatment in Chronic Hepatitis B in Two Late-Breaking Oral Presentations at AASLD The Liver Meeting® 2026
• 2026-08-28 — AusperBio Completes $120 Million Series C Financing to Advance AHB-137 Toward Potential Commercialization and Expand Next-Generation HBV Therapies

Appears alongside

• AASLD
• HBV

Browse the full archive →